CTVA — Corteva, Inc.

As of 2026-09-13, sentiment is constructive: Q2 2026 adjusted EPS of $2.30 beat consensus by $0.06 and management raised full-year guidance, while analysts maintain a Buy consensus with price targets of $95-$103. However, the stock fell 4.51% in the past week and revenue missed at $6.38B, highlighting soft farmer spending and crop-price pressure.

Revenue is highly seasonal but stabilizing: Q2 2026 revenue fell 1.2% YoY to $6.379B, while Q1 2026 rose 11.1% YoY to $4.905B. Q2 2026 operating margin expanded to 30.0% from 28.4% a year ago, though diluted EPS fell 9.9% to $1.73 on tax/other items. TTM operating margin is 17.1% with ROIC of 5.9%. Free cash flow is uneven: TTM FCF is only $629M due to Q1 2026 -$2.972B and Q2 2026 -$588M, but full-year 2025 FCF was $2.815B. The trend is margin improvement with seasonal cash-flow swings, not structural deterioration.

Trailing P/E of 55.6x is distorted by TTM EPS of $1.505. On next-FY consensus EPS of $3.752, the forward P/E is 22.4x. The 5-year average P/E is 37.6x, and P/S is 3.15x versus a 5-year average of 2.32x, so the deterministic score labels valuation Rich vs. its own history. We view shares as fairly valued to slightly rich on sales, but reasonable on forward earnings if the recovery materializes.

As of 2026-09-13, the market is pricing in a sharp adjusted-EPS recovery from $1.505 TTM to $3.752 next FY, plus value from the Vylor spin-off. The 11.08% one-month rally to $83.91 already reflects some optimism. If Q3 confirms margin expansion and the separation executes cleanly, upside toward analyst targets ($95-$103) exists; if crop prices stay depressed or FCF remains weak, the forward multiple could compress.

As of 2026-09-13, RSI(14) is 51.07, neutral. Price is 0.88% above the 20-day SMA, 0.54% above the 50-day SMA, and 7.88% above the 200-day SMA. The 1-week return is -4.51%, but 1-month is +11.08% and 3-month +10.19%. The trend is up, but the recent pullback and neutral RSI suggest waiting for stabilization near the 20/50-day SMAs or the September 15 investor day catalyst.

• Soft global crop commodity prices are pressuring farmer net income and baseline ag-input demand.
• Stabilized interest rate expectations are increasing scrutiny on capital-intensive ag businesses and free cash flow generation.
• Ongoing consolidation and innovation in ag inputs, including regulatory approvals for new seed traits and crop protection chemicals.
• Currency fluctuations and global trade dynamics affect international sales and input costs.
• Weather variability and regional pest pressure can cause significant seasonal swings in seed and crop protection volumes.

• September 15, 2026 investor days detailing the Vylor spin-off and standalone strategies for both entities.
• October 1, 2026 formal completion of the corporate separation into Vylor and new Corteva.
• Q3 2026 earnings release on November 3, 2026, the first period reflecting the streamlined structures.
• New product approvals and partnerships, including the Globachem joint venture and Rimisoxafen herbicide tech.
• Potential capital allocation actions such as buybacks or dividend increases after separation.

• Prolonged low crop prices could further reduce farmer spending and pressure volumes.
• Execution risk and trapped value in the Vylor spin-off, including dis-synergies and stranded costs.
• Weak free cash flow conversion: TTM FCF of $629M versus full-year 2025 FCF of $2.815B.
• Regulatory hurdles for new seed genetics and crop protection products in key markets.
• Rich valuation on sales (P/S 3.15x vs. 5-year average 2.32x) if the forward earnings recovery disappoints.

Corteva is a well-capitalized ag franchise with low debt (debt/equity 0.194), improving operating margins, and a major catalyst in the October 1, 2026 separation. However, trailing fundamentals are weak, free cash flow is uneven, and the stock trades rich on sales versus its own history. I'd rate it a hold/neutral: not a bargain, but the spin-off and forward EPS recovery could unlock value. Wait for execution proof.

Applied a 24.5x forward P/E to next-FY consensus EPS of $3.752, yielding $91.92 (rounded to $92.00). This multiple is a discount to the 5-year average trailing P/E of 37.6x, which is distorted by depressed earnings, and cross-checks with a ~13x forward EV/EBITDA on estimated forward EBITDA.